Imperial Chemical Industries Limited

Ici Pharma

Astrazeneca Ab

Zeneca Limited

University of Cape Town

Mmv Medicines for Malaria Venture

Zeneca Pharma

David Waterson

Nicholas John Newcombe

Howard Tucker

Philip N Edwards

Robert I Dowell

George R Brown

Maurice Raymond Verschoyle Finlay

Bernard Christophe Barlaam

Keith Oldham

Robin Wood

Michael John Witty

Pierre A Bruneau

Robert Antony Holt

Jeffrey Philip Poyser

Jonathan Hutton

Kelly Chibale

Justin Fairfield Bower

John F Kingston

Stuart Richard Rigby

Elaine Sophie Stokes

Robert Hugh Bradbury

David A Roberts

Thomas G Bird

Elaine Sophie Elizabeth Stokes

David J Brown

John Graham Cumming

Paul Turner

William J Watkins

Jon James Gordon Winter

Yassir Younis

Leslie Street

Diego Gonzalez Cabrera

Christophe B Barlaam

Maurice R V Finlay

Tanya Paquet

David Jonas Persson

Robert Ian Dowell

The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Anti-malarial agents

The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation. In one embodiment, the invention provides aminopyrazine derivatives having the following formula: 

Compounds of formula (I)Q-L-W&#x2014;C(&#x2550;X)&#x2014;Z&#x2014;Pwherein

Heterocyclic compounds as CCR2B antagonists

Formula (I) wherein Ris a (2-4C)alkyl and is substituted by two or more fluorine groups and Ris methyl or ethyl, or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by metalloproteinase enzymes. 

Hydantoin derivatives useful as metalloproteinase inhibitors

Compounds of formula (I) Q-L-W&#x2014;C(&#x2550;X)&#x2014;Z&#x2014;P wherein Q is an amine of the formula &#x2014;N(R)(R); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Yand Ywhich are linked to groups L and C(X) respectively and Yand Yare independently selected from N and C; X is O, N, N&#x2014;CN or S; Z is NR; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

Heterocyclic compounds as ccr2b antagonists

The invention provides compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein ring B represents a monocyclic aryl ring having six ring atoms or a monocyclic heteroaryl ring having up to six ring atoms and containing one or more ring heteroatoms wherein each said heteroatom is nitrogen; R2 represents a group selected from C1-6 alkyl or aryl, which said group is substituted by one or more fluorine groups; n is 1, 2 or 3; and R1 represents an optionally substituted group selected from C1-6 alkyl, C5-7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-6 alkyl-aryl, C1-6 alkyl-heteroaryl, C1-6 alkyl-cycloalkyl or C1-6 alkyl-heterocycloalkyl. Processes for their preparation; pharmaceutical compositions containing them; and their use in the treatment of a disease condition mediated by one or more metalloproteinase enzymes. 

N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13 

Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Metalloproteinase inhibitor compounds

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Compounds

Production of optically active 2-substituted tetrahydropyran-4-ones

Heterocyclic compounds useful as pharmaceutical agents

Substituted pyrimidine derivatives and their pharmaceutical use

Growing community of inventors

Macclesfield, United Kingdom

David Waterson